CA3102555A1 - Methods of treating malignant lymphoproliferative disorders - Google Patents

Methods of treating malignant lymphoproliferative disorders Download PDF

Info

Publication number
CA3102555A1
CA3102555A1 CA3102555A CA3102555A CA3102555A1 CA 3102555 A1 CA3102555 A1 CA 3102555A1 CA 3102555 A CA3102555 A CA 3102555A CA 3102555 A CA3102555 A CA 3102555A CA 3102555 A1 CA3102555 A1 CA 3102555A1
Authority
CA
Canada
Prior art keywords
cell
inhibitor
lymphoma
gsk
ing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102555A
Other languages
English (en)
French (fr)
Inventor
Francis Giles
Andrew Mazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actuate Therapeutics Inc
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of CA3102555A1 publication Critical patent/CA3102555A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3102555A 2018-06-05 2019-06-05 Methods of treating malignant lymphoproliferative disorders Pending CA3102555A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680739P 2018-06-05 2018-06-05
US62/680,739 2018-06-05
PCT/US2019/035576 WO2019236703A1 (en) 2018-06-05 2019-06-05 Methods of treating malignant lymphoproliferative disorders

Publications (1)

Publication Number Publication Date
CA3102555A1 true CA3102555A1 (en) 2019-12-12

Family

ID=68769443

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102555A Pending CA3102555A1 (en) 2018-06-05 2019-06-05 Methods of treating malignant lymphoproliferative disorders

Country Status (11)

Country Link
US (3) US11510904B2 (https=)
EP (1) EP3801768A4 (https=)
JP (2) JP7794564B2 (https=)
KR (1) KR20210045364A (https=)
CN (2) CN112351819B (https=)
AU (1) AU2019280693B2 (https=)
BR (1) BR112020024931A2 (https=)
CA (1) CA3102555A1 (https=)
IL (2) IL315565A (https=)
MX (2) MX2020013163A (https=)
WO (1) WO2019236703A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801768A4 (en) * 2018-06-05 2022-04-20 Actuate Therapeutics Inc. METHODS OF TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANT DISEASES
CN115697323A (zh) * 2019-12-26 2023-02-03 开动疗法公司 用于治疗骨髓纤维化的化合物
US20240009170A1 (en) * 2020-11-17 2024-01-11 Brown University Inhibition of glycogen synthase kinase-3 (gsk-3)
JP2022157223A (ja) * 2021-03-31 2022-10-14 国立大学法人神戸大学 抗ガン剤効果増強剤
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
WO2023172629A2 (en) * 2022-03-08 2023-09-14 Brown University Anticancer maleimide derivatives for use with immune checkpoint blockade
JP2025525407A (ja) * 2022-06-27 2025-08-05 アクチュエイト セラピューティクス インク． エルラグルシブの経口剤形
EP4565217A1 (en) * 2022-08-04 2025-06-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2025245059A1 (en) * 2024-05-23 2025-11-27 Yale University Compositions comprising gsk-3 and/or beta-catenin inhibitors and/or degraders and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
AU2013224302B2 (en) * 2012-02-21 2017-03-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US20160375006A1 (en) * 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
RS58700B1 (sr) 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
WO2014165851A1 (en) * 2013-04-05 2014-10-09 The Children's Hospital Of Philadelphia Transient up-regulation of myc in b-cell lymphomas
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
EP3801768A4 (en) * 2018-06-05 2022-04-20 Actuate Therapeutics Inc. METHODS OF TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANT DISEASES

Also Published As

Publication number Publication date
MX2020013163A (es) 2021-02-18
US20240366563A1 (en) 2024-11-07
MX2024008461A (es) 2024-07-19
IL315565A (en) 2024-11-01
KR20210045364A (ko) 2021-04-26
US20230126700A1 (en) 2023-04-27
CN112351819A (zh) 2021-02-09
WO2019236703A1 (en) 2019-12-12
IL279155B1 (en) 2024-10-01
JP2024096738A (ja) 2024-07-17
EP3801768A4 (en) 2022-04-20
AU2019280693B2 (en) 2024-10-10
JP7794564B2 (ja) 2026-01-06
AU2019280693A1 (en) 2020-12-03
US20210228546A1 (en) 2021-07-29
EP3801768A1 (en) 2021-04-14
CN117883438A (zh) 2024-04-16
IL279155A (en) 2021-01-31
IL279155B2 (en) 2025-02-01
CN112351819B (zh) 2023-11-10
BR112020024931A2 (pt) 2021-03-09
US11510904B2 (en) 2022-11-29
US11980607B2 (en) 2024-05-14
JP2021527039A (ja) 2021-10-11

Similar Documents

Publication Publication Date Title
US11980607B2 (en) Methods of treating malignant lymphoproliferative disorders
US9526915B2 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
KR20140008282A (ko) 혈액암의 치료
US20230414582A1 (en) Methods of treating diseases and disorders
AU2026201311A1 (en) Methods and dosing regimens comprising a CDK2 inhibitor and a CDK4 inhibitor for treating cancer
CN110062633A (zh) 酪氨酸衍生物以及包含所述酪氨酸衍生物的组合物
US20220034766A1 (en) Immunohistochemical staining for gsk-3
WO2021175824A1 (en) Method for administration of an anti cancer agent
AU2014247979B2 (en) Inhibitors of metastasis
US20230060792A1 (en) Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy
EP4719403A1 (en) Methods of treating cancer in bcl2 inhibitor naive subjects
US20210137953A1 (en) Inhibitors of Mcl-1 and Akt Binding, Pharmaceutical Compositions, and Uses in Treating Cancer
US20240342157A1 (en) Bak activators, pharmaceutical compositions, and uses in treating cancer
WO2024229440A2 (en) Methods of treating cancer using mdm2 inhibitors and compositions related thereto
WO2022120197A1 (en) Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies
WO2025090844A1 (en) Methods of treating cancer associated with reduced interleukin 1 beta expression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240604

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250613

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251014

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251120

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260120